(Q38080683)

28 August 2017

title

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis (English)

1 reference

Pauline A van Schouwenburg

28 August 2017

0 references

0 references

1 reference

object named as

Pauline A van Schouwenburg

series ordinal

1

0 references

author name string

Theo Rispens

series ordinal

2

1 reference

28 August 2017

Gerrit Jan Wolbink

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

12 February 2013

1 reference

Nature Reviews Rheumatology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

164-172

1 reference

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Neutralising antibodies against interferon beta in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immunogenicity of biological therapeutics: from assay to patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Etanercept and venous thromboembolism: a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Differential effect of drug interference in immunogenicity assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Antibody pharmacokinetics and pharmacodynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Antibody humanization: a case of the 'Emperor's new clothes'?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immunogenicity of therapeutic proteins: clinical implications and future prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Prevention and prediction of inhibitor risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Factors influencing the immunogenicity of therapeutic proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Human immune response to recombinant human proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Assessment of the antigenic response in humans to a recombinant mutant interferon beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Characterizing biological products and assessing comparability following manufacturing changes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Requirements for immune recognition and processing of factor VIII by antigen-presenting cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immunogenicity of therapeutic proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

The human immune response to the OKT3 monoclonal antibody is oligoclonal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Inhibition of human factor VIIIa by anti-A2 subunit antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Factor VIII polypeptide specificity of monoclonal anti-factor VIII antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Effects of protein aggregates: an immunologic perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Glycosylation of recombinant antibody therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.4

Unresolved issues in biologic therapy for rheumatoid arthritis

31 March 2020

1 reference

12 December 2020

Pure red-cell aplasia "epidemic"--mystery completely revealed?

1 reference

12 December 2020

Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

1 reference

12 December 2020

Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3

1 reference

12 December 2020

The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

1 reference

12 December 2020

A survey of applications of biological products for drug interference of immunogenicity assays

1 reference

12 December 2020

Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006

1 reference

12 December 2020

Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.

1 reference

12 December 2020

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

1 reference

12 December 2020

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1 reference

12 December 2020

Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response

1 reference

12 December 2020

Epitope specificity and functional characterization of factor VIII inhibitors

1 reference

12 December 2020

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group

1 reference

12 December 2020

Anti-factor VIII antibodies: a 2005 update.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.4

1 reference

Dimensions Publication ID

28 August 2017

1013238113

0 references

1 reference